Applying Clinical Evidence to Practice: DOPTELET® (avatrombopag) for Adult Patients with Chronic Immune Thrombocytopenia (ITP) Who Have Had an Insufficient Response to a Previous Treatment
April 29 @ 5:30 pm - 6:30 pm
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
This educational activity is directed toward medical oncologists, pathologists, surgical oncologists, and other clinicians involved in the management of cancer patients.
This event is complementary to MOASC Members but registration is required.
More details Here